CTSO
Cytosorbents CorpCompany Information
- Company Name
- Cytosorbents Corp
- CIK
- CIK0001175151
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- CTSO: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 08 Industrial Applications and Services
- SIC
- 3841
- SIC Description
- Surgical & Medical Instruments & Apparatus
- Ticker
- CTSO
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-09-15
- Last sale
- —
- Shares purchased (TTM)
- 318,680
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 16,034,382
- Shares outstanding
- 62,806,694
- Ownership
- 25.53%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- -15.79%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 4 | 5 | 6 | 8 | 10 | 12 | 3 | 6 | 8 | 9 | 14 | 8 | ||||||
| Restricted Cash Current | - | 2 | - | - | - | - | 5 | - | - | - | - | - | ||||||
| Accounts Receivable Net Current | 7 | 7 | 8 | 7 | 8 | 8 | 7 | 7 | 8 | 7 | 6 | 6 | ||||||
| Inventory Net | 4 | 4 | 5 | 4 | 4 | 3 | 3 | 3 | 4 | 4 | 3 | 3 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 2 | 2 | 1 | 3 | 3 | 1 | 1 | 1 | 2 | 2 | ||||||
| Assets Current | 16 | 18 | 21 | 21 | 23 | 25 | 22 | 17 | 22 | 20 | 25 | 19 | ||||||
| Property Plant And Equipment Net | 7 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | ||||||
| Restricted Cash Noncurrent | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 6 | 6 | 1 | 1 | 2 | ||||||
| Operating Lease Right Of Use Asset | 11 | 11 | 11 | 11 | 11 | 11 | 12 | 12 | 12 | 12 | 12 | 12 | ||||||
| Finite Lived Intangible Assets Net | 3 | 3 | 3 | - | - | - | 4 | - | - | - | - | - | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 4 | 4 | 4 | 0 | 4 | 4 | 4 | 4 | 4 | ||||||
| Assets | 38 | 41 | 44 | 46 | 48 | 51 | 47 | 48 | 53 | 47 | 53 | 48 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 2 | 4 | 3 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Long Term Debt Current | 14 | 7 | - | - | - | - | - | - | - | 3 | 3 | 1 | ||||||
| Liabilities Current | 24 | 16 | 10 | 10 | 10 | 10 | 10 | 8 | 10 | 13 | 14 | 12 | ||||||
| Operating Lease Liability Noncurrent | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 13 | 13 | 13 | 13 | 13 | ||||||
| Long Term Debt Noncurrent | 3 | 10 | 17 | 15 | 14 | 14 | 14 | 14 | 14 | 2 | 3 | 4 | ||||||
| Liabilities | 39 | 38 | 38 | 37 | 36 | 36 | 36 | 35 | 37 | 28 | 29 | 29 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 322 | 322 | 321 | 320 | 319 | 318 | 311 | 308 | 308 | 306 | 306 | 292 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -2 | -3 | -4 | -4 | 2 | 4 | -0 | 2 | 2 | 1 | 3 | ||||||
| Retained Earnings Accumulated Deficit | -322 | -317 | -312 | -307 | -304 | -305 | -304 | -295 | -293 | -289 | -283 | -277 | ||||||
| Stockholders Equity | -1 | 2 | 6 | 9 | 12 | 15 | 11 | 13 | 17 | 20 | 23 | 19 | ||||||
| Liabilities And Stockholders Equity | 38 | 41 | 44 | 46 | 48 | 51 | 47 | 48 | 53 | 47 | 53 | 48 | ||||||
| Allowance For Doubtful Accounts Receivable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | ||||||
| Common Stock Shares Issued | 63 | 63 | 63 | 63 | 63 | 63 | 55 | 55 | 54 | 54 | 54 | 44 | ||||||
| Shares Outstanding | 63 | 63 | 63 | 63 | 63 | 63 | 55 | 55 | 54 | 54 | 54 | 44 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCytosorbents Corp (CTSO) — SEC Financial Statements & Analysis
Cytosorbents Corp (CTSO) is a surgical & medical instruments & apparatus company, incorporated in DE. Cytosorbents Corp trades on Nasdaq as: CTSO. Cytosorbents Corp (CTSO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Cytosorbents Corp carries a market cap of $469.79M, a P/E ratio of -25.80x, a P/B ratio of -625.56x, a P/S ratio of 12.62x, an enterprise value of $481.10M, and an EV/EBITDA multiple of -41.91x. On profitability, it posts a gross margin of 71.61%, an operating margin of -34.74%, a net margin of -48.94%, a Return on Equity (ROE) of -336.17%, a Return on Assets (ROA) of -42.38%, and a Return on Invested Capital (ROIC) of -98.47%. Per share, it reports EPS of $-0.29, diluted EPS of $-0.29, free cash flow per share of $-0.15, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 3.07% year-over-year, net income growth of 84.56% year-over-year, and EPS growth of 83.98% year-over-year. On the balance sheet, it maintains a current ratio of 0.66x, a quick ratio of 0.47x, working capital of $-8.29M, a debt-to-equity ratio of -51.55x, a debt ratio of 1.02, an interest coverage ratio of -4.15x, free cash flow of $-9.33M (TTM), and net debt of $11.31M. Figures sourced from SEC EDGAR.
- Market Cap
- $469.79M
- P/E TTM
- -25.80x
- EPS TTM
- $-0.29
- P/B TTM
- -625.56x
- ROE TTM
- -336.17%
- ROA TTM
- -42.38%
- Debt To Equity
- -51.55x
- Free Cash Flow TTM
- $-9.33M
- Net Revenue TTM Growth 1Y
- 3.07%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Cytosorbents Corp in?
Cytosorbents Corp (CTSO) operates in the Surgical & Medical Instruments & Apparatus industry.
What exchange does CTSO trade on?
Cytosorbents Corp (CTSO) trades on the Nasdaq.
Where is Cytosorbents Corp incorporated?
Cytosorbents Corp is incorporated in DE.
When was Cytosorbents Corp (CTSO)'s most recent SEC filing?
Cytosorbents Corp (CTSO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is CTSO's market cap?
Cytosorbents Corp (CTSO) has a market capitalization of $469.79M as of 2026-06-30.
What is CTSO's EPS (earnings per share)?
Cytosorbents Corp (CTSO)'s trailing twelve month EPS is $-0.29 as of 2026-06-30.
What is CTSO's ROE (return on equity)?
Cytosorbents Corp (CTSO)'s trailing twelve month Return on Equity (ROE) is -336.17% as of 2026-06-30.
What is CTSO's ROA (return on assets)?
Cytosorbents Corp (CTSO)'s trailing twelve month Return on Assets (ROA) is -42.38% as of 2026-06-30.
What is CTSO's ROIC (return on invested capital)?
Cytosorbents Corp (CTSO)'s trailing twelve month Return on Invested Capital (ROIC) is -98.47% as of 2026-06-30.
What is CTSO's EV/EBITDA?
Cytosorbents Corp (CTSO)'s trailing twelve month EV/EBITDA is -41.91x as of 2026-06-30.